Leerink Partners reiterates Outperform rating on Kalvista stock as Ekterly launch begins

Kalvista Pharmaceuticals (KALV) shares surged 33% in the past week following FDA approval of Ekterly (sebetralstat), the first and only on-demand oral treatment for hereditary angioedema (HAE). This approval has prompted brokerages including Leerink, JMP, BofA, and Stifel to reiterate positive ratings and raise price targets, with JMP projecting peak sales of approximately $740 million for Ekterly, despite its $16,720 per dose wholesale acquisition cost. The company has initiated its U.S. launch and plans international expansion, positioning Ekterly as a significant oral alternative to existing injectable treatments.

Analysis

Kalvista Pharmaceuticals (KALV) has received a significant catalyst with the FDA's approval of Ekterly, the first and only oral on-demand treatment for hereditary angioedema (HAE). This approval addresses a key unmet need in a market previously reliant on injectable therapies, positioning the company for substantial market capture. The market has reacted strongly, with the stock surging 33% in the past week to trade near its 52-week high. The sentiment from the analyst community is uniformly positive, with multiple firms upgrading price targets; JMP Securities projects peak sales of approximately $740 million and set a $27 target, while BofA Securities and Stifel are even more bullish with targets of $37 and $39, respectively. The commercial launch is underway in the U.S. with a wholesale acquisition cost of $16,720 per dose, and Leerink Partners projects initial U.S. sales of $34.0 million in fiscal 2026. The company's expansion strategy appears robust, with an EMA decision anticipated in H2 2025 and commercialization agreements already secured for Japan and Canada, supported by what analysts describe as a strong cash balance to fund the launch.

Key Decisions for Investors

• Given the landmark FDA approval and strong analyst consensus with price targets significantly above the current trading price, investors could view the recent stock surge as validation of a compelling long-term growth narrative.
• It is critical to monitor the initial U.S. sales ramp-up and physician adoption rates for Ekterly, as successful commercial execution will be the primary determinant in achieving the projected peak sales of approximately $740 million.
• Key upcoming catalysts to watch are the European Medicines Agency (EMA) regulatory decision expected in the second half of 2025 and initial launch progress in international markets, which could further de-risk the global commercialization strategy.